{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:48:35Z","timestamp":1765295315194},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study assessed the impact of adherence to guidelines-recommended diagnostic testing on treatment selection and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) initiated on rituximab-based first line of treatment (1-LOT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study used a nationwide electronic health record-derived de-identified database, including diagnostic testing information on immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and karyotype analysis that were abstracted from pathology reports or clinical visit notes, where available. The study included patients above 18\u00a0years old who were diagnosed with DLBCL between January 2011 and December 2019 and initiated on rituximab-based 1-LOT. Patients were classified into \u2018non-adherence,\u2019 \u2018partial-adherence\u2019 and \u2018complete-adherence\u2019 groups according to the evidence\/documentation of a confirmed known result for IHC and molecular profiling tests (FISH and karyotyping) on a selection of the markers prior to the initiation of 1-LOT. Logistic regression was used to evaluate associations of adherence to diagnostic testing with 1-LOT between R-CHOP and other rituximab-based regimens. Median OS after the start of rituximab-based 1-LOT was calculated using the Kaplan\u2013Meier method. Multivariable-adjusted Cox proportional hazards regression was used to assess the risk of all-cause death after initiation of 1-LOT by the degrees of adherence to guidelines-recommended diagnostic testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 3730 patients with DLBCL who initiated on rituximab-based 1-LOT were included. No association was found between adherence to guidelines-recommended diagnostic testing and treatment selection of 1-LOT for R-CHOP versus other rituximab-based regimens. Patients with a higher degree of adherence to guidelines-recommended diagnostic testing survived longer (median OS at 5.1, 6.9 and 7.1\u00a0years for \u2018non-adherence,\u2019 \u2018partial-adherence\u2019 and \u2018complete-adherence\u2019 groups, respectively [log-rank <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001]) and had a decreased mortality risk (multivariable-adjusted hazard ratio with 95% confidence intervals at 0.83 [0.70\u20130.99] for \u2018partial-adherence\u2019 and 0.77 [0.64\u20130.91] for \u2018complete-adherence\u2019 groups, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients\u2019 adherence to guidelines-recommended diagnostic testing were associated with better survival benefit, reinforcing the need for adoption of diagnostic testing guidelines in routine clinical care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04179-8","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T03:38:26Z","timestamp":1660707506000},"page":"3691-3700","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study"],"prefix":"10.1007","volume":"149","author":[{"given":"Fei","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie T.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Prime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"4179_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503\u2013511","journal-title":"Nature"},{"key":"4179_CR2","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","volume":"28","author":"S Barrans","year":"2010","unstructured":"Barrans S, Crouch S, Smith A et al (2010) Rearrangement of MYC Is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360\u20133365","journal-title":"J Clin Oncol"},{"key":"4179_CR3","doi-asserted-by":"publisher","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al (2020) Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. https:\/\/doi.org\/10.48550\/arXiv.2001.09765","DOI":"10.48550\/arXiv.2001.09765"},{"key":"4179_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690","journal-title":"Nat Med"},{"key":"4179_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J et al (2002) CHOP Chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Medicine 346:235\u2013242","journal-title":"New Engl J Medicine"},{"key":"4179_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.6065\/apem.2017.22.2.90","volume":"22","author":"M Fukami","year":"2017","unstructured":"Fukami M, Miyado M (2017) Next generation sequencing and array-based comparative genomic hybridization for molecular diagnosis of pediatric endocrine disorders. Ann Pediatric Endocrinol Metabolism 22:90\u201394","journal-title":"Ann Pediatric Endocrinol Metabolism"},{"key":"4179_CR7","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1177\/1460458219899841","volume":"26","author":"RD Hammer","year":"2020","unstructured":"Hammer RD, Prime MS (2020) A clinician\u2019s perspective on co-developing and co-implementing a digital tumor board solution. Health Inform J 26:2213\u20132221","journal-title":"Health Inform J"},{"key":"4179_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/CCI.20.00029","volume":"4","author":"RD Hammer","year":"2020","unstructured":"Hammer RD, Fowler D, Sheets LR et al (2020) Digital Tumor Board Solutions Have Significant Impact on Case Preparation. Jco Clin Cancer Informatics 4:757\u2013768","journal-title":"Jco Clin Cancer Informatics"},{"key":"4179_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282","journal-title":"Blood"},{"key":"4179_CR10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2016.70.0765","volume":"35","author":"LH Jakobsen","year":"2017","unstructured":"Jakobsen LH, B\u00f8gsted M, de Brown P et al (2017) Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. J Clin Oncol 35:778\u2013784","journal-title":"J Clin Oncol"},{"key":"4179_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2217\/fon-2018-0388","volume":"15","author":"W Jurczak","year":"2019","unstructured":"Jurczak W, Dugosz-Danecka M, Navarro FR (2019) The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. Future Oncol 15:305\u2013317","journal-title":"Future Oncol"},{"key":"4179_CR12","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS et al (2008) Stromal gene signatures in large-B-cell lymphomas. New Engl J Medicine 359:2313\u20132323","journal-title":"New Engl J Medicine"},{"key":"4179_CR13","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.18632\/oncotarget.27785","volume":"11","author":"N Lodhi","year":"2020","unstructured":"Lodhi N, Tun M, Nagpal P et al (2020) Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget 11:4045\u20134073","journal-title":"Oncotarget"},{"key":"4179_CR14","doi-asserted-by":"publisher","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS (2020) Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. https:\/\/doi.org\/10.1101\/2020.03.16.20037143","DOI":"10.1101\/2020.03.16.20037143"},{"key":"4179_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais J-P et al (2014) Event-Free Survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:1066\u20131073","journal-title":"J Clin Oncol"},{"key":"4179_CR16","unstructured":"NCCN Guidelines: B-Cell Lymphomas Version 5.2021 [Internet]. National Comprehensive Cancer Network , 2021[cited 2022 Feb 4] Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"4179_CR17","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e449","author":"GS Nowakowski","year":"2015","unstructured":"Nowakowski GS, Czuczman MS (2015) ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e449","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4179_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41408-019-0208-6","volume":"9","author":"GS Nowakowski","year":"2019","unstructured":"Nowakowski GS, Feldman T, Rimsza LM et al (2019) Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J 9:48","journal-title":"Blood Cancer J"},{"key":"4179_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.leu.2404449","volume":"21","author":"PD Paepe","year":"2007","unstructured":"Paepe PD, Wolf-Peeters CD (2007) Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 21:37\u201343","journal-title":"Leukemia"},{"key":"4179_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/107327481201900306","volume":"19","author":"AM Perry","year":"2012","unstructured":"Perry AM, Mitrovic Z, Chan WC (2012) biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 19:214\u2013226","journal-title":"Cancer Control"},{"key":"4179_CR21","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124:4622\u20134632","journal-title":"Cancer"},{"key":"4179_CR22","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Medicine 346:1937\u20131947","journal-title":"New Engl J Medicine"},{"key":"4179_CR23","unstructured":"SEER Cancer Stat Facts: NHL - Diffuse Large B-Cell Lymphoma (DLBCL) [Internet]. SEER [cited 2022 Jan 27] Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"4179_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbmt.2007.11.013","volume":"14","author":"T Seshadri","year":"2008","unstructured":"Seshadri T, Kuruvilla J, Crump M et al (2008) Salvage therapy for relapsed\/refractory diffuse large B cell lymphoma. Biol Blood Marrow Tr 14:259\u2013267","journal-title":"Biol Blood Marrow Tr"},{"key":"4179_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK (2021) 2021 Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol 96:617\u2013629","journal-title":"Am J Hematol"},{"key":"4179_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"4179_CR27","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1200\/JCO.2006.05.5897","volume":"24","author":"GW van Imhoff","year":"2006","unstructured":"van Imhoff GW, Boerma E-JG, van der Holt B et al (2006) Prognostic Impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24:4135\u20134142","journal-title":"J Clin Oncol"},{"key":"4179_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fonc.2018.00351","volume":"8","author":"J Zhang","year":"2018","unstructured":"Zhang J, Medeiros LJ, Young KH (2018) Cancer immunotherapy in diffuse large B-cell lymphoma. Frontiers Oncol 8:351","journal-title":"Frontiers Oncol"},{"key":"4179_CR29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/1475-6773.13669","volume":"56","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Gossai A, Monroe S et al (2021) Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States. Health Serv Res 56:1281\u20131287","journal-title":"Health Serv Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04179-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04179-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04179-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:11:49Z","timestamp":1688213509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04179-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4179"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04179-8","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FY, JZ, JTY, and MSP are employed by and hold shares in Roche; RDH provides consultancy and receives honoraria and research funding from Roche; AA has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board approval of the study protocol was obtained prior to study conduct and included a waiver of informed consent. The IRB name was WCG IRB, and the registration number was\u00a0IRB00000533.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Institutional Review Board approval of the study protocol was obtained prior to study conduct and included a waiver of informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}